Dr E MacLeod

🟠 LBA109 – DISCUS: 3 vs 6 cycles of platinum-based chemotherapy before Avelumab maintenance in advanced urothelial carcinoma 👨‍⚕️ Presented by Dr. Enrique Grande (@drenriquegrande) #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ Phase II DISCUS compared 3 vs 6 cycles of platinum-based chemotherapy (cis/gem or carbo/gem) before Avelumab maintenance in untreated advanced UC. ⚡ N = 267; 133 (3C) vs 134 (6C). ⭐ QoL improved with 3C → +8.5 points (p = 0.016). 💡 OS: 18.9 mo in both arms (HR 1.15; p = 0.56). 👉 PFS: 8.0 vs 9.0 mo (HR 1.05; p = 0.79). ⚠️ Grade 3–4 TRAEs: 11.9% (3C) vs 15.7% (6C). 🔆 Conclusion: Shorter induction (3 cycles) followed by Avelumab maintenance preserves efficacy while improving QoL — supporting treatment de-escalation in advanced UC. @DrChoueiri @MyriamChalabi @myESMO #Berlin 🔗 @montypal @DrDanielHeng @VivekSubbiah @HHammersMD @Uromigos #BladderCancer #Avelumab #DISCUS #GU25 #ESMO25 #Oncology #ClinicalTrials

It's definitely progress to have treatment options for #MIBC & the results are compelling. Remember follow up is short - lots of censoring in both arms I'm old - been hearing about the demise of #RT in favour of systemic for years & yet...@myESMO #ESMO25

The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks. ✅ LBA6 — Phase 3 trial of [¹⁷⁷Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAaddition) ✅LBA86 — Randomised phase 3 trial of ADT with radiation therapy with or without enzalutamide for high-risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303) ✅2383O — Capivasertib + abiraterone vs placebo + abiraterone in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281 ✅LBA87 — EMBARK: OS with enzalutamide in biochemically recurrent prostate cancer ✅LBA93 — RAMPART: Adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma ✅2591O — Efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma: results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker ✅LBA2 — Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905 ✅LBA7 — Disitamab vedotin plus toripalimab vs chemotherapy in first-line locally advanced or metastatic urothelial carcinoma with HER2-expression ✅LBA8 — IMvigor011: A phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer ✅LBA109 — DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer ✅LBA111 — Randomized comparison of upfront MRI versus transurethral resection for staging new bladder cancers: final survival analysis from the BladderPath trial ✅LBA37 — Avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemo (ALPACA) Senior Faculty 🇨🇭 Dr. Gillessen 🇺🇸Dr. Agarwal 🇺🇸Dr. Zhang 🇺🇸Dr. Rini 🇺🇸Dr. Grivas 🇬🇧 Dr. Chowdhury AF Collaborators 🇧🇷 Dr. Melao 🇮🇳 Dr. Jain @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @ReginaBarCar